Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OTLK
Strong SellHot AirOutlook Therapeutics, Inc. · Healthcare · United States · $156M · Avg Vol: $11M/d
14
StockRankGet insider-trade alerts
Q
10
V
25
M
58
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
COMPANY DESCRIPTION
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 1.4M | — | 1.4M | 0.8M | 58.0M | 540.5% |
| EPS | — | -0.29 | -0.26 | -0.40 | -0.40 | — | -0.70 | -0.42 | -0.14 | — |
| Shares | — | 242.7M | 242.7M | 242.7M | 242.7M | 0.0% | 242.7M | — | — | — |
| Debt | — | 11.0M | 35.6M | 29.7M | 30.2M | 40.2% | 18.4M | — | — | — |
| Equity | — | 8.7M | -14.4M | -73.1M | -32.2M | — | — | — | — | — |
| Op CF | — | -56.7M | -43.0M | -68.8M | -51.8M | — | -56.2M | — | — | — |
| Inv CF | 0 | — | — | — | — | — | — | — | — | — |
| Fin CF | — | 59.6M | 49.0M | 60.3M | 45.0M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-36.4%
SMA 50SMA 200
Close
$0.661
RSI (14)
47.0
52W High
$2.54
From 52W High
0.3%
SCORE BREAKDOWN
Quality
10
ROIC (ROA)
-143.2%*4.3
ROE
—N/A
GP/Assets
-12.2%6.2
Op. Margin
-124255.3%0.6
FCF/Assets
-201.0%0.7
Piotroski
321.9
Int. Cover
-50.0x5.9
D/E Ratio
—N/A
Current Ratio
0.81x6.0
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-3.1x25.0
P/FCF
—N/A
P/B
-11.9x25.0
P/S
-139.0x25.0
Div Yield
—N/A
Momentum
58
52W High %
26%5.9
RS 6M
40%89.5
SMA 50/200
1.23x89.6
EPS Rev 4W
+12.5%91.2
EPS Rev 12W
—N/A
EPS Improve
+80%68.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$156M
P/E (Forward)
-4.8x
Gross Margin
4.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OTLK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc.(you) | $156M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
| INDP | Indaptus Therapeutics, Inc. | $152M | 13 | Strong Sell |
| SPRB | Spruce Biosciences, Inc. | $175M | 13 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| KRRO | Korro Bio, Inc. | $190M | 17 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 16 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%